Cannabis Legalization

Cannabis Conclave in Davos im Jahr 2020

Zum zweiten Mal in der Schweiz mit genauen Legalisierungsvorstellungen

2019 gab es eine Premiere auf dem Weltwirtschaftsforum in den Schweizer Gefilden um Davos. Menschen aus dem Cannabis-Business und Experten auf dem Gebiet luden zum geselligen Stelldichein ein und besprachen in exquisiter Atmosphäre die abgeschlossenen Entwicklungen und die Zukunft der Cannabis-Branche. Auch in diesem Jahr bot sich in Davos die Gelegenheit, mit den Geschäftemachern des speziellen Sektors und mit aufgeschlossenen Personen aus der Politik ins Gespräch zu kommen, um die Weichen für eine bessere Zukunft zu stellen. Dass es endlich an der Zeit für eine zeitgemäße Anpassung in der Drogen- und Gesundheitspolitik ist, bewies die Cannabis Conclave in Davos im Jahr 2020 erneut.

Auch im Jahr 2020 brachte die Cannabis Conclave verschiedene Führungskräfte der Cannabisindustrie, einige globale Investoren sowie politische Entscheidungsträger und internationale Medien zusammen, um die weltweite Legalisierungsdebatte – sowohl für Freizeit- als auch für medizinisches Cannabis – angemessen voranzutreiben und die wachsende Legitimität und Reife der legalen Cannabisindustrie hervorzuheben. Am 23. Januar fand das besondere Event statt, das unter anderem von dem North American Affairs Manager des Consumer Choice Center David Clement initiiert wurde. Im Gespräch mit dem Medical Cannabis Network gab Clement einige Details bekannt, die ihn zu seinem Engagement führten, welches er vor, während und nach den Tagen des Weltwirtschaftsforums benötigte und benötigen wird. „Sowohl auf internationaler als auch auf nationaler Ebene ist das Hauptproblem in der Thematik, dass die Gesetzgebung nicht auf Verbraucher oder Patienten ausgerichtet ist. Legalisierungsgesetze, ob im medizinischen Bereich oder bezüglich des Freizeitgebrauches, sollten immer den Zugang und die Erschwinglichkeit in den Vordergrund stellen. Leider ist dies in vielen Bereichen nicht der Fall. Es ist an der Zeit, dass internationale Gremien erkennen, dass der Krieg gegen Drogen ein Misserfolg ist, insbesondere wenn es um Cannabis geht. Ich denke, dass alle Länder in der Lage sein sollten, Cannabisvorschriften entsprechend ihren spezifischen Bedürfnissen zu erlassen. Trotzdem möchte ich alle Regierungen nachdrücklich ermutigen, den Krieg gegen Drogen aufzugeben und Cannabis zu legalisieren.“ Weiter führt David Clement an, dass es mehr Länder geben müsste, die sich dem Beispiel Kanadas annehmen und so zu einem internationalen Umschwung führen. „Die Legitimität der Branche kann dadurch gefestigt werden, dass weitere Länder die Legalisierung von Medizinalhanf und Freizeitgebrauch übernehmen. Kanada hat trotz seiner regulatorischen Fehler einen Kurs festgelegt, auf dem andere Länder diesem Beispiel folgen können. Wir sind zuversichtlich, dass in naher Zukunft ein Wendepunkt auf internationaler Ebene ansteht, wenn immer mehr Länder die Legalisierung übernehmen.“ Dass sich zumindest peu à peu etwas bewegt, ließ Clement dabei nicht unerwähnt. „Die großen Entwicklungen für Cannabis im Jahr 2020 werden neue Rechtsordnungen sein, die eine Legalisierung umfassen. Wir wissen, dass Luxemburg und Malta derzeit prüfen, wie ihr Legalisierungsprozess tatsächlich aussehen könnte. Ein großes Thema dieser beiden Länder ist die Frage, wie viel sie von Kanada lernen können. Wir hoffen beispielsweise, dass diese beiden Länder, obwohl sie die Legalisierung befürworten, eine Überregulierung von Cannabis vermeiden werden, wie sie in Kanada stattfand.“ Was er damit genau meint, führt der Affairs Manager des Consumer Choice Center auch an. „Nur durch patienten- und verbraucherfreundliche Vorschriften kann sichergestellt werden, dass die Legalisierung erfolgreich ist und der Schwarzmarkt verdrängt wird.“ Positiv wird David Clement auch dadurch gestimmt, dass die Welt nun mittlerweile ernsthaft zuhöre, wenn es um das Thema der Cannabislegalisierung geht – dies hätte ihm die Cannabis Conclave im Jahr 2020 in Davos bewiesen.

Der dort ebenfalls anwesende Stephen Murphy von Prohibition Partners sagte dazu in einem Interview mit Benzinga, dass es mit Cannabis erst jetzt vorangehe. Es fehlten derzeit noch die großen Marken auf dem Markt, sodass noch viel Platz für Teilnehmer übrig sei, die sich in dem vielversprechenden Geschäftsfeld versuchen wollen. Er betonte zudem, dass Cannabis zahlreiche Branchen abdeckt, darunter Getränke, Lebensmittel, Gesundheitswesen, Schönheitspflege, Wellness, Bauwesen, Textilien, Ingenieurwesen, Technologie, Tierpflege, Biokraftstoffe und sogar Bettwäsche. In den vergangenen drei Jahren, seitdem man seitens Prohibition Partners die Branche beobachte, habe dennoch bereits ein erstaunliches Wachstum stattgefunden, das nun weit über die damals fünf bis sechs existierenden Märkte reichen würde. Zudem gäbe es Hunderttausende von Menschen auf der ganzen Welt, die medizinisches Cannabis konsumierten, und man habe mittlerweile signifikante Beweise dafür, dass alleine diese Tatsache eine Umsetzung von neuen Gesetzen rechtfertige, sagte er. Man könne derzeit bestimmte Einstufungen benutzen, um den Zugang zu Cannabis in den unterschiedlichsten Ländern zu beschreiben. Es wäre daher eine sehr eingeschränkte und verzerrte Denkweise, wenn Menschen in Großbritannien verzweifelt an Cannabis zu medizinischen Zwecken gelangen wollten – dies aber nicht dürften, weil es von offizieller Stelle „nicht genug Daten“ gäbe – während in Israel und Kanada Personen damit schon lange behandelt werden. Immerhin habe man mittlerweile auch einen immer stärken Druck auf die unterschiedlichen Regulierungsbehörden feststellen können, welche allesamt eigene Gesetze, Richtlinien und Anträge zum Thema Cannabis besitzen. Es gäbe daher nun auch große Möglichkeiten für die Forschung und den allgemeinen Fortschritt, die die aktuell noch bestehenden großen Wissenslücken schrumpfen lassen könnten, welche global endlich unbedingt geschlossen werden müssten.

Legalize – worldwide!

Originally published here.


The Consumer Choice Center is the consumer advocacy group supporting lifestyle freedom, innovation, privacy, science, and consumer choice. The main policy areas we focus on are digital, mobility, lifestyle & consumer goods, and health & science.

The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at consumerchoicecenter.org

Cannabis Conclave 2020 Dubbed The ‘Rebels Of Davos’

Last week, the Cannabis Conclave took place in Davos, Switzerland. The event was dubbed by some as the “rebellious side” of Davos.

The Conclave was hosted by the Consumer Choice Center and Prohibition Partners.

“The event featured industry leaders, investors and policy makers from over 25 different countries. The purpose of the event is to continue to fuel the legalization debate internationally,” David Clement, North American Affairs Manager at Consumer Choice Center, told Benzinga.

Legalizing Cannabis

“Fueling the legalization debate, and the advancement of legalization, requires three things,” Clement said. “First, we need policy makers who are open to the idea, and who realize that the war on drugs is failing. Second, we need entrepreneurs who want to enter the legal space and meet the demand of consumers and patients.”

Clement said the industry needs investors to help catapult it forward so it can expand, and ultimately stamp out the black market.

“That is why we bring those three groups together in Davos. One headline called us the ‘Rebels of Davos,’ explaining that the Cannabis Conclave is the sharper, more daring edge of what goes on during the World Economic Forum,” Clement said.

The team is committed to returning in 2021.

Listen to Yaël Ossowski and Clement on Consumer Choice Radio discuss the Cannabis Conclave further here: https://consumerchoicecenter.org/radio/ep3/

Originally published here.


The Consumer Choice Center is the consumer advocacy group supporting lifestyle freedom, innovation, privacy, science, and consumer choice. The main policy areas we focus on are digital, mobility, lifestyle & consumer goods, and health & science.

The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at 
consumerchoicecenter.org

Davos cannabis conclave advances cause for legalisation

The second annual, premier cannabis industry event – the Cannabis Conclave – returned to Davos this January to bring together industry leaders and policy makers.

This year the Cannabis Conclave brought together cannabis industry executives, global investors, policy makers and international media to fuel the legalisation debate globally, both for recreational and medical cannabis, and to highlight the growing legitimacy and maturity of the legal cannabis industry.

The Consumer Choice Center organised the event that took place in Davos, Switzerland on 23 January, 2020.

Medical Cannabis Network spoke to organiser, David Clement, to find out more.

Cannabis Conclave 2020

As the world’s most influential executives, activists, and change makers descend on Davos, the conclave aimed to bring cannabis to the front and centre of the global discussion.

Clement, North American Affairs Manager with the Consumer Choice Center, said: “Both internationally and domestically, the number one issue is that legislation is not consumer or patient focussed. Legalisation bills, whether medical or recreational, should always be putting access and affordability first. Unfortunately, in many instances this is not the case. It is time for international bodies to realise that the war on drugs is a failure, especially its focus on cannabis.

“I think that countries should be able to craft cannabis regulations to suit their specifics needs. That being said, I’d strongly encourage all governments to abandon the war on drugs and to legalise cannabis.”

The high-end networking that occurs at the conclave ensures the right amount of knowledge sharing for future collaborations, and for smarter consumer focussed policy.

Clements said: “The legitimacy of the industry can be cemented by having additional countries embrace medical and recreational legalisation. Canada, despite its regulatory mistakes, has charted a course for other countries to follow their lead. We are hopeful that as more countries adopt legalisation, that a tipping point internationally is in the near future.”

Cannabis in 2020

2020 has been earmarked as a big year for cannabis – with expectations that both recreational and medicinal cannabis will become much more ‘normalised’.

Clements said: “The big developments for cannabis in 2020 will be new jurisdictions embracing legalisation. We know that Luxembourg and Malta are now currently reviewing what their legalisation process could look like. One big theme from those two countries is the question of how much they will learn from Canada? For example, it is our hope that while embracing legalisation that those two countries avoid over-regulating cannabis like Canada did.

“Having patient friendly and consumer friendly regulations is the only way to ensure that legalisati on is a success, and that the black market is stamped out.”

He added: “One big takeaway from Cannabis Conclave 2020 is that the world is now listening when it comes to cannabis legalisation.”

Originally published here.


The Consumer Choice Center is the consumer advocacy group supporting lifestyle freedom, innovation, privacy, science, and consumer choice. The main policy areas we focus on are digital, mobility, lifestyle & consumer goods, and health & science.

The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at 
consumerchoicecenter.org

NOBL Completes Series A Funding Round At Davos, Altitude Investment Management Among Round Participants

Cannabis data and consulting company NOBL said Thursday it finalized its Series A fundraise at Davos and capital support of £1.25 million ($1.64 million).

Altitude Investment Management, Enexis AB and Artemis Growth Partners are some of the dominant cannabis investors who have supported the round.

Closing our Series A with the caliber of investors we’ve brought in is indicative of our performance and reputation. We are proven to understand global markets, launch sector leading brands and operate tenacious companies that deliver month on month revenue growth” Co-Founder, Stephen Murphy, said in a statement at NOBL’s co-hosted Cannabis Conclave event in Davos.

NOBL offers a portfolio platform that contains some of the leading companies and brands in the industry, such as Atalis, European Cannabis Weeks, Prohibition Partners, NOBL Live and Cannabis Europa.

“We will continue to invest in talent and innovation while also enabling our operating companies to make smarter and more effective business decisions that will shape the future of the global cannabis industry in a meaningful and impactful way,” Murphy said.

Michael Goldberg, Partner at Altitude Investment Management, stated, “We have been collaborating with the team at NOBL over the last two years and are pleased to invest in this financing round as NOBL continues to shape the future of global cannabis through knowledge and intelligence with its superior data, insights, and networking opportunities.”

Davos 2020 Cannabis Conclave: Uncovering The Future Of The European Market

Medical cannabis in Europe has slowly been gaining traction, but there are still a number of hurdles around regulation that has a lot of catching up to do.

Speaking at the Cannabis Conclave event in Davos, Switzerland last week, Stephen Murphy of Prohibition Partners discussed medical cannabis policy and the importance of knowledge sharing across the continent.

Murphy said big brands have yet to enter the cannabis market, so less competition exists compared to other industries. The market correction offers a window of opportunity for new brands, businesses and ideas to be generated. He stressed cannabis covers numerous industries such as beverages, food, healthcare, beauty, wellness, construction, textiles, engineering, technology, pet care, biofuel and bedding.

“When we first started monitoring and identifying what’s happening in the cannabis space, there were five to six legal markets over the three years we have seen that grow,” said Murphy, who noted the CDB market in particular is really taking off.

“There are hundreds of thousands of people using medical cannabis across the world and we have significant evidence already in place that it justifies the implementation of legislation,” he said.

“I think we can put phases in place in terms of access levels to cannabis. The implication of medical cannabis’ availability in Israel and Canada when there are patients in the UK desperately trying to get access and cannot because ‘there is not enough data’ is very skewed thinking.”

Murphy said we have started to see a lot of pressure on regulatory bodies all of which have bills, policies and motions around cannabis. There are also major opportunities in R&D and there is a huge knowledge gap that needs to be filled.

Originally published here.


The Consumer Choice Center is the consumer advocacy group supporting lifestyle freedom, innovation, privacy, science, and consumer choice. The main policy areas we focus on are digital, mobility, lifestyle & consumer goods, and health & science.

The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at 
consumerchoicecenter.org

Cannabis Industry Gathers In Davos: ‘No Silver Bullet Gets Rid Of An Illegal Product’

Cannabis Industry Gathers In Davos: 'No Silver Bullet Gets Rid Of An Illegal Product'

The World Economic Forum (WEF) in Davos, Switzerland, took place this week and alongside the main event there was a cluster of small cozy cannabis gatherings hosted in the Alps.

Switzerland is one of my favorite countries for a business trip and this week I experienced the ultimate luxury which involved sipping champagne and discussing pot – and the vibe was very much on point.

Business leaders, financial heavyweights and leading politicians from all over the world gathered to discuss key issues revolving around climate change and sustainable business. It’s estimated around 119 billionaires and 53 heads of state attended this year.

The Cannabis Conclave was a huge hit the previous year – an event hosted by David Clement from the Consumer Choice Center. The event was well attended by hedge fund managers and regulators, attracting crowds from Canada, Switzerland, Europe, Israel and China. Many discussions centered around the rapidly growing cannabis industry and how conservative countries are also adopting the recreational drug.

Canada was the second country, after Uruguay, to make cannabis federally legal and as a result took a cautious and in some times instances took a limited approach that has stifled both product availability as well as distribution chains.

What Can We Learn From Canada?

One Canadian government official at Davos who asked to remain anonymous explained: “Our federal government downloaded key aspects to provincial and municipal counterparts that created a disparate and disconnected set of frameworks creating confusion and a wide variety of structures across the country.”

He explained there has been clear winners such as Alberta that has a robust retail and production framework while Ontario has continually been lambasted for a slow and painful rollout that has reduced the success of legalization in the key market in the country.

“As a result we have clear winners and losers and there is much to learn from our experience. As the frameworks and mis-steps are remedied as like any new industry there will be meaningful lessons to be learned,” he explained.

He went on to add no country charting new ground has everything right and in some ways the black market has remained as vibrant as ever whose diminishment was the core cause.

“No silver bullet gets rid of an illegal product, but only meaningful policy that suits the customer and their wallet is effective and the correct approach, market forces should be listened to,” he said.

The Hurdles Of Cannabis

Over champagne, the official added a meaningful lesson for America is to ensure there are no disconnects between states and the federal government that currently persist that has limited proper regulation across the country and in particular created technical and practical problems for the legal industry that continues to give breath and vibrancy to the illicit market.

Stephen Murphy, co-founder of NOBL, highlighted the cannabis plant remains a great unknown with only 3% of the plant meaningfully studied. He stressed there is huge potential of the remaining 97% from a health, economic and social perspective.

Originally published here.


The Consumer Choice Center is the consumer advocacy group supporting lifestyle freedom, innovation, privacy, science, and consumer choice. The main policy areas we focus on are digital, mobility, lifestyle & consumer goods, and health & science.

The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at 
consumerchoicecenter.org

Pot Industry Heads to Davos as Stocks Rebound: Cannabis Weekly

Tough times in the cannabis industry aren’t stopping its leaders from going to Davos.

For the second year in a row, there will be a Cannabis House in Davos, Switzerland this week alongside the schmoozing and speeches of the World Economic Forum. The 2020 offering promises to be “a little more formal and more professional” than last year’s, according to Jason Paltrowitz, executive vice president of corporate services at OTC Markets Group, one of the sponsors of the Cannabis House.

Cannabis House will feature a two-day conference focused on the themes of Davos 2020, including sustainability, climate change, social equity and impact investing.

The rout in pot stocks hasn’t dampened interest in the event, which will also include “a professional capital markets discussion,” Paltrowitz said.

The agenda has an international flavor, with speakers from Israel, Switzerland and Asia.

The goal is to get delegates from the World Economic Forum to pop in and learn about the industry, said Richard Carleton, chief executive officer of the Canadian Securities Exchange, another sponsor.

“What was particularly interesting to me last year was how many European institutional investors, everybody from family office managers, hedge funds, right up to some of the largest pension funds in the world” stopped by Cannabis House, Carleton said. “They hadn’t invested yet but were there to learn.”

Stock Rebound

Investors seemed to be in the mood to celebrate successes rather than punish failures last week.

Pot stocks ended the week significantly higher, with the BI Global Cannabis Competitive Peers Index up 15% and the Canadian-focused Horizons Marijuana Life Sciences Index ETF adding 18%, its biggest weekly increase since August 2018. The gains came despite Aphria Inc.’s earnings miss and cut to its full-year guidance, which sent its shares down 8.6% on Tuesday.

Instead, investors focused on positive results from Aphria’s smaller competitor Organigram Holdings Inc. Organigram’s U.S.-traded shares surged 45% Wednesday after it reported positive adjusted Ebitda and revenue that beat the highest analyst estimate. That sent the entire sector rallying, and even Aphria’s shares ended the week higher.

Given how fast investors have been to punish missteps in recent months, could this be a sign that the sector has bottomed out?

There are positive signs in the capital markets too, according to data from Viridian Capital Advisors. In the first two weeks of 2020, seven capital raises worth a total of $250 million were completed. Although the number of deals was lower than the 15 done in the first two weeks of 2019, the average deal size was more than 2.5 times bigger than the same period of last year, Viridian said.

Events This Week

MONDAY 1/20

  • Cannabis House hosts “a global cannabis conversation” in Davos, Switzerland alongside the World Economic Forum, through Jan. 21
  • U.S. markets closed for Martin Luther King Jr. Day

WEDNESDAY 1/22

  • CannaWest addresses regulatory issues in the industry; the event runs in Los Angeles through Jan. 24

THURSDAY 1/23


Originally published here.

Het rebelse kantje van Davos

Cannabis, blockchain, gaming: in het ‘officiële’ programma van het World Economic Forum kom je die zaken niet snel tegen. Maar Davos heeft ook een scherper, meer gedurfd randje.

Originally published here.

Cannabis Conclave Returning To Davos: Meet Benzinga At The Event

The Cannabis Conclave is returning to Davos on Jan. 23, alongside the World Economic Forum.

The Conclave, which is hosted by the Consumer Choice Center and Prohibition Partners, is an industry event that seeks to connect industry leaders, investors and policy makers. The purpose of the event is to advance the legalization discussion internationally, for both medical and recreational cannabis.

The event consists of a networking luncheon at the mountainside Restaurant Höhenweg, where guests will be treated to a full Swiss three course lunch, along with thought provoking presentations.

“We are excited to be back in Davos for our second annual Cannabis Conclave. This year we will have industry leaders from 24 countries in attendance. Our event will ensure that cannabis policy remains front and center as the world’s most influential people descend on Davos for the week,” David Clement, North American Affairs Manager at Consumer Choice Center, told Benzinga.

Originally published here.


The Consumer Choice Center is the consumer advocacy group supporting lifestyle freedom, innovation, privacy, science, and consumer choice. The main policy areas we focus on are digital, mobility, lifestyle & consumer goods, and health & science.

The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at 
consumerchoicecenter.org

What NZ can learn from Canada’s cannabis experiment

New Zealand and Canada, despite being 13,000 kilometres apart, have a lot in common. Both countries are small in terms of population, punch above their weight economically, and are politically compassionate.

If New Zealand is to succeed where Canada has failed in legalising cannabis, it needs to create a more consumer-friendly regulatory regime, says Clement.

If New Zealand votes to legalise cannabis in 2020, that will be one more similarity that these two Commonwealth countries will share.

The draft policy positions for New Zealand’s cannabis referendum have been released, and for the most part, they mirror what Canada has done for recreational cannabis legalisation.

As a Canadian, I can tell you that legalising cannabis is the right thing to do. I can also say that New Zealand should avoid the regulatory approach that Canada took.

There are several mistakes that Canada made which New Zealand should steer clear of replicating.

The first major one is the failure to differentiate between THC products and non-intoxicating CBD products.

The draft policy positions state that any product produced from the cannabis plant is to be considered a cannabis product. This puts CBD products that are not intoxicating on par with THC products that are.

If New Zealand is to succeed where Canada has failed in legalising cannabis, it needs to create a more consumer-friendly regulatory regime, says Clement.

Following what Canada has done fails to regulate based on a continuum of risk, and runs against the New Zealand Government’s goal of harm reduction.

If the Government cares about minimising harm, it shouldn’t regulate non-intoxicating low-risk products the same way as intoxicating psychoactive ones. Harm reduction should mean making the least harmful products more available, not less available.

The second major mistake in the draft policy positions is the ban on all cannabis advertising. This proposal takes Canada’s very paternalistic advertising laws and exceeds them.

Complete marketing and advertising bans for legal cannabis products are misguided for two reasons. The first is that they are wildly inconsistent with how New Zealand treats other age-restricted goods, such as alcohol. Alcohol has a much higher risk profile when compared to cannabis, but does not have such strict advertising rules.

The second reason is that a complete ban fails to properly understand the role marketing has in moving consumers over from the black market. Modest forms of marketing allow for the legal market to attract existing consumers, who are buying cannabis illegally, into the legal framework.

Legal cannabis accounts for only about 20 per cent of all cannabis consumed in Canada, and that is in large part because the legal industry is handcuffed by regulations that stop them attracting consumers from the black market.

For purchases, and a personal carry limit, the proposed policy is that no New Zealander be allowed to purchase more than 14g of cannabis a day, and that no-one should exceed carrying more than 14g on their person in public. This is extreme when compared to Canada’s 30g limit, and inconsistent when compared to alcohol, which has no purchase or personal limit. It is reasonable to assume that the people criminalised by this arbitrary limit will be the same who were most harmed by prohibition: the marginalised.

Lastly are the policies on potency and taxation. The Government wants to establish a THC potency limit for cannabis products, which is understandable.

That said, whatever the limit is, the Government should avoid setting it too low. If the limit is excessively low, consumers are likely to smoke more to get their desired THC amount. That runs directly against the Government’s harm reduction approach. Secondly, if the limit is too low, it creates a clear signal for black-market actors that there is a niche to fill.

It is important to keep taxation modest, so that pricing can be competitive between the legal and illegal markets. Canada’s onerous excise, sales, and regional taxes can increase the price of legal cannabis by upwards of 29 per cent.

Poor tax policy in Canada is in large part why legal cannabis can be more than 50 per cent more expensive than black-market alternatives. Incentivising consumers to stay in the black market hurts consumer safety, and cuts the Government out of tax revenue entirely.

New Zealand is on the right path regarding cannabis legalisation, but it is important that regulators learn lessons from Canada’s process. For the sake of harm reduction, and stamping out the black market, it is vital that New Zealand has a consumer-friendly regulatory regime, one that specifically avoids, and not replicates, the mistakes made in Canada.


The Consumer Choice Center is the consumer advocacy group supporting lifestyle freedom, innovation, privacy, science, and consumer choice. The main policy areas we focus on are digital, mobility, lifestyle & consumer goods, and health & science.

The CCC represents consumers in over 100 countries across the globe. We closely monitor regulatory trends in Ottawa, Washington, Brussels, Geneva and other hotspots of regulation and inform and activate consumers to fight for #ConsumerChoice. Learn more at 
consumerchoicecenter.org

Scroll to top